{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:25:03Z","timestamp":1790915103421,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T00:00:00Z","timestamp":1565913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T00:00:00Z","timestamp":1565913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CP17\/00179"],"award-info":[{"award-number":["CP17\/00179"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The identification of exclusive markers to target HIV-reservoir cells will represent a significant advance in the search for therapies to cure HIV. Here, we identify the B lymphocyte antigen CD20 as a marker for HIV-infected cells in vitro and in vivo. The CD20 molecule is dimly expressed in a subpopulation of CD4-positive (CD4<jats:sup>+<\/jats:sup>) T lymphocytes from blood, with high levels of cell activation and heterogeneous memory phenotypes. In lymph node samples from infected patients, CD20 is present in productively HIV-infected cells, and ex vivo viral infection selectively upregulates the expression of CD20 during early infection. In samples from patients on antiretroviral therapy (ART) this subpopulation is significantly enriched in HIV transcripts, and the anti-CD20 monoclonal antibody Rituximab induces cell killing, which reduces the pool of HIV-expressing cells when combined with latency reversal agents. We provide a tool for targeting this active HIV-reservoir after viral reactivation in patients while on ART.<\/jats:p>","DOI":"10.1038\/s41467-019-11556-4","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T10:15:23Z","timestamp":1565950523000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1413-3990","authenticated-orcid":false,"given":"Carla","family":"Serra-Peinado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9350-2429","authenticated-orcid":false,"given":"Judith","family":"Grau-Exp\u00f3sito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9515-5889","authenticated-orcid":false,"given":"Laura","family":"Luque-Ballesteros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Astorga-Gamaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7187-0367","authenticated-orcid":false,"given":"Jordi","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Gallego-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6435-0374","authenticated-orcid":false,"given":"Mario","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1263-0814","authenticated-orcid":false,"given":"Adri\u00e0","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8445-3047","authenticated-orcid":false,"given":"Joaquin","family":"Burgos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3752-8808","authenticated-orcid":false,"given":"Esteban","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4668-2970","authenticated-orcid":false,"given":"Berta","family":"Ravent\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7791-3682","authenticated-orcid":false,"given":"Rein","family":"Willekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1848-5096","authenticated-orcid":false,"given":"Ariadna","family":"Torrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1490-7127","authenticated-orcid":false,"given":"Bibiana","family":"Planas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8222-5697","authenticated-orcid":false,"given":"Rosa","family":"Bad\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7658-5832","authenticated-orcid":false,"given":"Felipe","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5745-9996","authenticated-orcid":false,"given":"Josep","family":"Castellv\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meritxell","family":"Genesc\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9626-0023","authenticated-orcid":false,"given":"Vicen\u00e7","family":"Falc\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4427-9413","authenticated-orcid":false,"given":"Maria J.","family":"Buzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,16]]},"reference":[{"key":"11556_CR1","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/j.1365-2796.2011.02457.x","volume":"270","author":"S Palmer","year":"2011","unstructured":"Palmer, S., Josefsson, L. & Coffin, J. M. HIV reservoirs and the possibility of a cure for HIV infection. J. Intern. Med. Suppl. 270, 550\u2013560 (2011).","journal-title":"J. Intern. Med. Suppl."},{"key":"11556_CR2","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrmicro2223","volume":"7","author":"M Coiras","year":"2009","unstructured":"Coiras, M., Lopez-Huertas, M. R., Perez-Olmeda, M. & Alcami, J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat. Rev. Microbiol. 7, 798\u2013812 (2009).","journal-title":"Nat. Rev. Microbiol."},{"issue":"430","key":"11556_CR3","doi-asserted-by":"publisher","first-page":"eaap9927","DOI":"10.1126\/scitranslmed.aap9927","volume":"10","author":"Steven A. Yukl","year":"2018","unstructured":"Yukl, S. A. et al. HIV latency in isolated patient CD4(+) T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing. Sci. Transl. Med. 10, eaap9927 (2018).","journal-title":"Science Translational Medicine"},{"key":"11556_CR4","doi-asserted-by":"crossref","unstructured":"Grau-Exp\u00f3sito, J. S.-P. C. et al. A novel single-cell FISH-flow assay identifies effector memory CD4 T cells as a major niche for HIV-1 transcription in HIV-infected patients. mBIO 8, e00876-17 (2017).","DOI":"10.1128\/mBio.00876-17"},{"key":"11556_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-10-41","volume":"10","author":"AO Pasternak","year":"2013","unstructured":"Pasternak, A. O., Lukashov, V. V. & Berkhout, B. Cell-associated HIV RNA: a dynamic biomarker of viral persistence. Retrovirology 10, 41 (2013).","journal-title":"Retrovirology"},{"key":"11556_CR6","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/S2352-3018(14)70014-1","volume":"1","author":"TA Rasmussen","year":"2014","unstructured":"Rasmussen, T. A. et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1\/2, single group, clinical trial. Lancet HIV 1, e13\u2013e21 (2014).","journal-title":"Lancet HIV"},{"key":"11556_CR7","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1016\/S2352-3018(16)30055-8","volume":"3","author":"S Leth","year":"2016","unstructured":"Leth, S. et al. Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B\/2A trial. Lancet HIV 3, e463\u2013e472 (2016).","journal-title":"Lancet HIV"},{"key":"11556_CR8","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nature11286","volume":"487","author":"NM Archin","year":"2012","unstructured":"Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482\u2013485 (2012).","journal-title":"Nature"},{"key":"11556_CR9","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1002\/art.24998","volume":"60","author":"E Wilk","year":"2009","unstructured":"Wilk, E. et al. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum. 60, 3563\u20133571 (2009).","journal-title":"Arthritis Rheum."},{"key":"11556_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.imlet.2012.05.004","volume":"146","author":"F Forster","year":"2012","unstructured":"Forster, F., Singla, A., Arora, S. K., Schmidt, R. E. & Jacobs, R. CD20+ T cell numbers are decreased in untreated HIV-1 patients and recover after HAART. Immunol. Lett. 146, 74\u201378 (2012).","journal-title":"Immunol. Lett."},{"key":"11556_CR11","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4049\/jimmunol.1400118","volume":"193","author":"A Palanichamy","year":"2014","unstructured":"Palanichamy, A. et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J. Immunol. 193, 580\u2013586 (2014).","journal-title":"J. Immunol."},{"key":"11556_CR12","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/cyto.990140212","volume":"14","author":"LE Hultin","year":"1993","unstructured":"Hultin, L. E., Hausner, M. A., Hultin, P. M. & Giorgi, J. V. CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry 14, 196\u2013204 (1993).","journal-title":"Cytometry"},{"key":"11556_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","volume":"40","author":"JC Edwards","year":"2001","unstructured":"Edwards, J. C. & Cambridge, G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 40, 205\u2013211 (2001).","journal-title":"Rheumatology"},{"key":"11556_CR14","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards, J. C. et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572\u20132581 (2004).","journal-title":"N. Engl. J. Med."},{"key":"11556_CR15","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1084\/jem.187.6.949","volume":"187","author":"K Tenner-Racz","year":"1998","unstructured":"Tenner-Racz, K. et al. The unenlarged lymph nodes of HIV-1-infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation. The impact of highly active antiretroviral therapy. J. Exp. Med. 187, 949\u2013959 (1998).","journal-title":"J. Exp. Med."},{"key":"11556_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.20411\/pai.v1i1.100","volume":"1","author":"C Deleage","year":"2016","unstructured":"Deleage, C. et al. Defining HIV and SIV reservoirs in lymphoid tissues. Pathog. Immun. 1, 68\u2013106 (2016).","journal-title":"Pathog. Immun."},{"issue":"437","key":"11556_CR17","doi-asserted-by":"publisher","first-page":"eaar6759","DOI":"10.1126\/scitranslmed.aar6759","volume":"10","author":"Mohamed Abdel-Mohsen","year":"2018","unstructured":"Abdel-Mohsen, M. et al. CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. Sci. Trans. Med. 10, eaar6759 (2018).","journal-title":"Science Translational Medicine"},{"key":"11556_CR18","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney, D. G. et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood 90, 2188\u20132195 (1997).","journal-title":"Blood"},{"key":"11556_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jim.2005.09.018","volume":"308","author":"VR Gomez-Roman","year":"2006","unstructured":"Gomez-Roman, V. R. et al. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J. Immunol. Methods 308, 53\u201367 (2006).","journal-title":"J. Immunol. Methods"},{"key":"11556_CR20","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1126\/science.1165706","volume":"323","author":"DD Richman","year":"2009","unstructured":"Richman, D. D. et al. The challenge of finding a cure for HIV infection. Science 323, 1304\u20131307 (2009).","journal-title":"Science"},{"key":"11556_CR21","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1126\/science.1191047","volume":"329","author":"D Trono","year":"2010","unstructured":"Trono, D. et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 329, 174\u2013180 (2010).","journal-title":"Science"},{"key":"11556_CR22","doi-asserted-by":"publisher","first-page":"E20","DOI":"10.1038\/s41586-018-0495-2","volume":"561","author":"CE Osuna","year":"2018","unstructured":"Osuna, C. E. et al. Evidence that CD32a does not mark the HIV-1 latent reservoir. Nature 561, E20\u2013E28 (2018).","journal-title":"Nature"},{"key":"11556_CR23","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1086\/314451","volume":"178","author":"JM Orendi","year":"1998","unstructured":"Orendi, J. M. et al. Activation and cell cycle antigens in CD4+ and CD8+ T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection. J. Infect. Dis. 178, 1279\u20131287 (1998).","journal-title":"J. Infect. Dis."},{"key":"11556_CR24","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/COH.0000000000000230","volume":"11","author":"M Massanella","year":"2016","unstructured":"Massanella, M., Fromentin, R. & Chomont, N. Residual inflammation and viral reservoirs: alliance against an HIV cure. Curr. Opin. HIV AIDS 11, 234\u2013241 (2016).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"11556_CR25","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.4049\/jimmunol.1600089","volume":"197","author":"E Schuh","year":"2016","unstructured":"Schuh, E. et al. Features of human CD3+CD20+ T cells. J. Immunol. 197, 1111\u20131117 (2016).","journal-title":"J. Immunol."},{"key":"11556_CR26","doi-asserted-by":"publisher","first-page":"e999536","DOI":"10.1080\/2162402X.2014.999536","volume":"4","author":"M de Bruyn","year":"2015","unstructured":"de Bruyn, M. et al. CD20(+) T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer. Oncoimmunology 4, e999536 (2015).","journal-title":"Oncoimmunology"},{"key":"11556_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nm.3445","volume":"20","author":"MJ Buzon","year":"2014","unstructured":"Buzon, M. J. et al. HIV-1 persistence in CD4+ T cells with stem cell-like properties. Nat. Med. 20, 139\u2013142 (2014).","journal-title":"Nat. Med."},{"key":"11556_CR28","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nm.1972","volume":"15","author":"N Chomont","year":"2009","unstructured":"Chomont, N. et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15, 893\u2013900 (2009).","journal-title":"Nat. Med."},{"issue":"4","key":"11556_CR29","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/QAI.0000000000001622","volume":"77","author":"Melanie Wittner","year":"2018","unstructured":"Melanie Wittner, G. A. D. et al. CD32 expression of different memory T cell subpopulations in the blood and lymph nodal tissue of HIV patients and healthy controls correlates with immune activation. J. Acquir. Immune. Defic. Syndr. 77, 345\u2013349 (2018).","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"key":"11556_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05157-w","volume":"9","author":"R Badia","year":"2018","unstructured":"Badia, R. et al. CD32 expression is associated to T-cell activation and is not a marker of the HIV-1 reservoir. Nat. Commun. 9, 2739 (2018).","journal-title":"Nat. Commun."},{"key":"11556_CR31","doi-asserted-by":"publisher","first-page":"e1006856","DOI":"10.1371\/journal.ppat.1006856","volume":"14","author":"LE Hogan","year":"2018","unstructured":"Hogan, L. E. et al. Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30. PLoS. Pathog. 14, e1006856 (2018).","journal-title":"PLoS. Pathog."},{"key":"11556_CR32","doi-asserted-by":"crossref","unstructured":"Markle, T. J., Philip, M. & Brockman, M. A. HIV-1 Nef and T-cell activation: a history of contradictions. Future Virol. 8, 391\u2013404 (2013).","DOI":"10.2217\/fvl.13.20"},{"key":"11556_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nature16933","volume":"530","author":"R Lorenzo-Redondo","year":"2016","unstructured":"Lorenzo-Redondo, R. et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature 530, 51\u201356 (2016).","journal-title":"Nature"},{"key":"11556_CR34","doi-asserted-by":"publisher","first-page":"6975","DOI":"10.4049\/jimmunol.178.11.6975","volume":"178","author":"E Connick","year":"2007","unstructured":"Connick, E. et al. CTL fail to accumulate at sites of HIV-1 replication in lymphoid tissue. J. Immunol. 178, 6975\u20136983 (2007).","journal-title":"J. Immunol."},{"key":"11556_CR35","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1089\/aid.2005.21.363","volume":"21","author":"JM Folkvord","year":"2005","unstructured":"Folkvord, J. M., Armon, C. & Connick, E. Lymphoid follicles are sites of heightened human immunodeficiency virus type 1 (HIV-1) replication and reduced antiretroviral effector mechanisms. AIDS Res. Hum. Retrovir. 21, 363\u2013370 (2005).","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"11556_CR36","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/nm.3781","volume":"21","author":"Y Fukazawa","year":"2015","unstructured":"Fukazawa, Y. et al. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat. Med. 21, 132\u2013139 (2015).","journal-title":"Nat. Med."},{"key":"11556_CR37","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1084\/jem.20121932","volume":"210","author":"M Perreau","year":"2013","unstructured":"Perreau, M. et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J. Exp. Med. 210, 143\u2013156 (2013).","journal-title":"J. Exp. Med."},{"key":"11556_CR38","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00262-011-1168-2","volume":"61","author":"D Stroopinsky","year":"2012","unstructured":"Stroopinsky, D., Katz, T., Rowe, J. M., Melamed, D. & Avivi, I. Rituximab-induced direct inhibition of T-cell activation. Cancer Immunol., Immunother. 61, 1233\u20131241 (2012).","journal-title":"Cancer Immunol., Immunother."},{"key":"11556_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jneuroim.2006.06.029","volume":"180","author":"AH Cross","year":"2006","unstructured":"Cross, A. H., Stark, J. L., Lauber, J., Ramsbottom, M. J. & Lyons, J. A. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 180, 63\u201370 (2006).","journal-title":"J. Neuroimmunol."},{"key":"11556_CR40","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1001\/archneurol.2010.99","volume":"67","author":"L Piccio","year":"2010","unstructured":"Piccio, L. et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch. Neurol. 67, 707\u2013714 (2010).","journal-title":"Arch. Neurol."},{"key":"11556_CR41","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1182\/blood-2008-09-177741","volume":"113","author":"T Gaufin","year":"2009","unstructured":"Gaufin, T. et al. Limited ability of humoral immune responses in control of viremia during infection with SIVsmmD215 strain. Blood 113, 4250\u20134261 (2009).","journal-title":"Blood"},{"key":"11556_CR42","doi-asserted-by":"publisher","first-page":"10347","DOI":"10.1128\/JVI.00880-09","volume":"83","author":"T Gaufin","year":"2009","unstructured":"Gaufin, T. et al. Effect of B-cell depletion on viral replication and clinical outcome of simian immunodeficiency virus infection in a natural host. J. Virol. 83, 10347\u201310357 (2009).","journal-title":"J. Virol."},{"key":"11556_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1100","volume":"1","author":"KH Huang","year":"2010","unstructured":"Huang, K. H. et al. B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. Nat. Commun. 1, 102 (2010).","journal-title":"Nat. Commun."},{"key":"11556_CR44","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fimmu.2018.00020","volume":"9","author":"MP Bronnimann","year":"2018","unstructured":"Bronnimann, M. P., Skinner, P. J. & Connick, E. The B-cell follicle in HIV infection: barrier to a Cure. Front. Immunol. 9, 20 (2018).","journal-title":"Front. Immunol."},{"key":"11556_CR45","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/infdis\/jix265","volume":"216","author":"TJ Henrich","year":"2017","unstructured":"Henrich, T. J. et al. Human immunodeficiency virus type 1 persistence following systemic chemotherapy for malignancy. J. Infect. Dis. 216, 254\u2013262 (2017).","journal-title":"J. Infect. Dis."},{"key":"11556_CR46","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/QAD.0000000000000974","volume":"30","author":"S Leth","year":"2016","unstructured":"Leth, S. et al. HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapy. AIDS 30, 713\u2013721 (2016).","journal-title":"AIDS"},{"key":"11556_CR47","doi-asserted-by":"publisher","first-page":"11776","DOI":"10.1128\/JVI.01730-06","volume":"80","author":"M Li","year":"2006","unstructured":"Li, M. et al. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J. Virol. 80, 11776\u201311790 (2006).","journal-title":"J. Virol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11556-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11556-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11556-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:50:19Z","timestamp":1671238219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11556-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,16]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["11556"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-11556-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,16]]},"assertion":[{"value":"16 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests. This work was produced solely by the authors and that no other individuals or entities influenced any aspects of the work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3705"}}